AbstrakKanker payudara (KPD) usia muda (≤40 tahun) merupakan kasus yang jarang. Angka kejadiannya kurang dari 7% dari semua wanita yang didiagnosa kanker payudara. KPD usia muda berhubungan dengan progresifitas yang tinggi, kecenderungan untuk rekurensi dan prognosis yang lebih buruk dibandingkan KPD usia tua. Penelitian ini bertujuan untuk menilai outcome dari pasien KPD usia muda yang mendapatkan pengobatan di RSUP Dr. M. Djamil Padang dari tahun 2008-2017. Desain penelitian ini adalah kohort retrospektif dengan analisis data menggunakan Kaplan Meier dengan Log Rank, pada 71 pasien yang telah didiagnosis KPD secara histopatologi dan mendapatkan terapi (bedah, kemoterapi, radioterapi, hormonal terapi ataupun targetting terapi). Hasil penelitian menunjukkan insiden KPD terbanyak pada range usia 35-40 tahun, dengan ukuran tumor T3, diferensiasi derajat sedang, histopatologi tipe duktal karsinoma dengan Triple Negative Breast Cancer (TNBC) sebagai subtipe yang terbanyak. Disease Free Survival (DFS) didapatkan rata-rata 87.48 bulan dan Overall Survival (OS) sebesar 79.13 bulan. Ukuran tumor didapatkan sebagai faktor yang berhubungan terhadap DFS (p = 0.00).Kata kunci: Kanker payudara usia muda, disease free survival, overall survival. AbstractBreast cancer in young woman (≤40 years) is a rare case. The incidence represents less than 7% of women diagnosed with breast cancer. Young breast cancer case is related with high progresivity, probability of recurrency and poor prognoses, compare with the breast cancer in older age. This study aimed to know the outcome of young breast cancer patients who got therapy at M. Djamil hospital Padang in year 2008-2017. The design of this study is retrospective cohort with data processed using Kaplan Meier with Log Rank. Of 71 eligible patients in this study had been diagnosed histopathologically and received various breast cancer therapies including surgery, chemotherapy, radiotherapy, hormonal therapy or targeting therapy. The result shows the highest incident of young breast cancer is at a range of age 35-40 years, with T3 size of the tumor, moderate differentiation, ductal type carcinoma, and Triple Negative Breast Cancer (TNBC) as the highest subtype. Disease Free Survival was 87.48 months and Overall Survival was 79.13 months. This study concludes that the size of the tumor is a factor that relate to Disease Free Survival (p = 0.00).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.